As of 2025-10-30, the Relative Valuation of Travere Therapeutics Inc (TVTX) is (33.76) USD. This relative valuation is based on P/E multiples. With the latest stock price at 29.98 USD, the upside of Travere Therapeutics Inc based on Relative Valuation is -212.6%.
The range of the Relative Valuation is (32.77) - (38.73) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 6.9x - 20.4x | 15.5x |
| Forward P/E multiples | 17.3x - 27.1x | 20.1x |
| Fair Price | (32.77) - (38.73) | (33.76) |
| Upside | -209.3% - -229.2% | -212.6% |
| Date | P/E |
| 2025-10-30 | -15.69 |
| 2025-10-29 | -15.81 |
| 2025-10-28 | -15.72 |
| 2025-10-27 | -15.70 |
| 2025-10-24 | -14.80 |
| 2025-10-23 | -14.84 |
| 2025-10-22 | -14.49 |
| 2025-10-21 | -14.66 |
| 2025-10-20 | -14.71 |
| 2025-10-17 | -14.41 |
| 2025-10-16 | -14.51 |
| 2025-10-15 | -14.16 |
| 2025-10-14 | -13.78 |
| 2025-10-13 | -13.81 |
| 2025-10-10 | -13.27 |
| 2025-10-09 | -13.75 |
| 2025-10-08 | -13.81 |
| 2025-10-07 | -13.45 |
| 2025-10-06 | -13.78 |
| 2025-10-03 | -12.99 |
| 2025-10-02 | -12.77 |
| 2025-10-01 | -13.07 |
| 2025-09-30 | -12.60 |
| 2025-09-29 | -12.68 |
| 2025-09-26 | -13.34 |
| 2025-09-25 | -12.97 |
| 2025-09-24 | -12.87 |
| 2025-09-23 | -12.78 |
| 2025-09-22 | -13.41 |
| 2025-09-19 | -13.10 |
| 2025-09-18 | -12.75 |
| 2025-09-17 | -12.47 |
| 2025-09-16 | -12.01 |
| 2025-09-15 | -12.13 |
| 2025-09-12 | -12.38 |
| 2025-09-11 | -13.18 |
| 2025-09-10 | -14.40 |
| 2025-09-09 | -11.41 |
| 2025-09-08 | -11.18 |
| 2025-09-05 | -11.41 |
| 2025-09-04 | -11.15 |
| 2025-09-03 | -10.34 |
| 2025-09-02 | -9.57 |
| 2025-08-29 | -9.23 |
| 2025-08-28 | -9.33 |
| 2025-08-27 | -9.20 |
| 2025-08-26 | -9.20 |
| 2025-08-25 | -9.09 |
| 2025-08-22 | -9.45 |
| 2025-08-21 | -9.38 |